Aminobisphosphonates as new weapons for gammadelta T Cell-based immunotherapy of cancer.
Several observations in mice and in humans have collectively laid the foundation for examining the potential of gammadelta T cells to exert tumor immunotherapy. Human gammaDelta T cells can be activated in a non-MHC dependent fashion either by low molecular mass phosphoantigens, or by agents that provoke the accumulation of endogenous pyrophosphates such as isopentenylpyrophosphate. Among the latter, aminobisphosphonates are well-established in the clinic, and extensive data are available on the compounds' antiangiogenic, antiosteolytic and pro-apoptotic properties. In this review we discuss on the possibility that the intentional activation of gammadelta T cells in vivo by aminobisphosphonates may represent a promising target for the design of novel and highly innovative immunotherapy in patients with different types of cancer.
Caccamo
Nadia
N
Dipartimento di Biopatologia e Metodologie Biomediche, Università di Palermo, Corso Tukory 211, Palermo 90134 Italy.
Meraviglia
Serena
S
Cicero
Giuseppe
G
Gulotta
Gaspare
G
Moschella
Francesco
F
Cordova
Adriana
A
Gulotta
Eliana
E
Salerno
Alfredo
A
Dieli
Francesco
F
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D045744:Cell Line, Tumor; D004164:Diphosphonates / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D017368:Protein Prenylation; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000187:drug effects* / Q000276:immunology*; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*
D000276:Adjuvants, Immunologic; D004164:Diphosphonates; D016692:Receptors, Antigen, T-Cell, gamma-delta